Phio Pharmaceuticals Announces First US Patient Enrolled In Phase 1B Clinical Trial With Intratumoral PH-762 Anti-PD-1 Therapy For Treatment Of Skin Carcinomas
Portfolio Pulse from Benzinga Newsdesk
Phio Pharmaceuticals has announced the enrollment of the first US patient in a Phase 1B clinical trial for intratumoral PH-762 Anti-PD-1 therapy for the treatment of skin carcinomas. This marks a significant step in the company's clinical development program.
November 09, 2023 | 12:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Phio Pharmaceuticals' enrollment of the first US patient in a Phase 1B clinical trial for PH-762 Anti-PD-1 therapy could potentially boost investor confidence in the company's clinical development program.
The enrollment of the first US patient in the Phase 1B clinical trial for PH-762 Anti-PD-1 therapy marks a significant milestone in Phio Pharmaceuticals' clinical development program. This could potentially boost investor confidence in the company's ability to progress its clinical trials and bring its therapies to market, which could have a positive impact on its stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100